期刊文献+

以发热为首要表现的华氏巨球蛋白血症1例并文献复习 被引量:1

下载PDF
导出
摘要 目的提高对不典型临床表现的华氏巨球蛋白血症(Waldenstr9m's macroglobulinemia,WM)的认识及诊治水平。方法对1例以发热为首要表现的WM患者的临床资料进行回顾性分析。结果诊断本病需结合骨髓检查、免疫电泳、流式细胞学、病理学检查,治疗推荐以利妥昔单抗、硼替佐米为基础的化疗。结论 WM起病隐匿,病程长,发病率低,临床表现无特异性,对于长期发热经抗感染治疗后无明显好转的患者,需考虑是否存在WM的可能。
出处 《成都医学院学报》 CAS 2017年第4期529-532,共4页 Journal of Chengdu Medical College
  • 相关文献

二级参考文献24

  • 1Swerdlow SH, Campo E, Harris NL, et al. World Health Organi- zation Classification of Tumours of Haematopoietie and Lymphoid Tissue [ M ]. 4th ed. Lyon:IARC Press, 2008:194-195.
  • 2Owen RG, Treon SP, A1-Katib A, et al. Clinicopathological definition of Waldenslrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia [J]. Semin Oncol, 2003, 30(2): 110-115.
  • 3Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr6m' s maeroglobulinemia [J]. N Engl J Med, 2012, 367 ( 9 ) :826-833.
  • 4Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia[J]. Blood, 2009, 113 ( 18 ): 4163-4170.
  • 5Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom' s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) [J]. Leuk Res, 2010, 34 ( 10): 1340-1343.
  • 6Kastritis E, Zervas K, Repoussis P, et al. Prognostication inyoung and old patients with Waldenstr6m's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase [J]. Clin Lymphoma Myeloma, 2009, 9( 1 ): 50-52.
  • 7Treon SP. How I treat Waldenstr6m macroglobulinemia [J]. Blood, 2009, 114(12): 2375-2385.
  • 8Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreat- ed Waldenstr6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma [J]. J Clin Oncol, 2013, 31 (3): 301-307.
  • 9Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstr6m macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98) [J]. Leuk Lymphoma, 2004, 45 (10): 2047- 2055.
  • 10Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobu- linemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol, 2007, 25(12): 1570-1575.

共引文献59

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部